LY341495 is an antagonist of metabotropic glutamate receptor (IC50s: 2.9 nM, 10 nM, 170 nM for mGluR-2, mGluR-3, mGluR-8, respectively).

LY341495 (3 mg/kg, i.p., 2.5 h) -induced c-Fos expression is not altered in either KO brain. LY341495 (3.0 mg/kg) reduces Dvl-2, pGSK-3α/β, and β-catenin protein levels but Dvl-1, Dvl-3, and GSK-3α/β are unaffected in both the PFC and STR. LY341495 (0.3, 1, and 3 mg/kg, i.p.) shows a lower level of discrimination in rats[1]. LY341495 has generally the opposite effect following acute and chronic administration compared to mGlu2/3 agonist, LY379268[2]. LY341495 is almost inactive in the central extended amygdala [central nucleus of the amygdala, lateral (CeL) and bed nucleus of the stria terminalis, laterodorsal (BSTLD)] in mGluR3-KO mice[3].

201943-63-7

C20H19NO5

353.37

DMSO:6 mg/mL (16.98 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years